Mitapivat and Lurasidone: Interaction Details

Brand names
Lurasidone
Latuda
Mitapivat
PyrukyndAqvesme
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
Share

Share this interaction

Mitapivat

Brand names
  • Pyrukynd
  • Aqvesme

What Happens When You Take Mitapivat With Lurasidone

What can happen when they are taken together (rated Major)

Reduced exposure

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

Mitapivat should not be used together with sensitive CYP3A substrates that have a . Because mitapivat induces CYP3A, giving it with a sensitive CYP3A substrate lowers the substrate's exposure.1

When cannot be avoided, patients should be monitored for loss of therapeutic effect. In drug interaction studies, midazolam (a sensitive CYP3A substrate) given with mitapivat showed dose-related reductions in (inf) and : 21% and 19% with mitapivat 5 mg twice daily, 43% and 39% with 20 mg twice daily, and 57% and 52% with 50 mg twice daily, respectively.2 With mitapivat 100 mg twice daily, midazolam AUC (inf) and Cmax were reduced by 65% and 59%, respectively.1

The Mitapivat and Lurasidone Interaction, Explained

Lurasidone (Latuda) is an used for schizophrenia and bipolar depression. Your body breaks it down mainly with an enzyme called . Mitapivat (Pyrukynd) speeds up that enzyme, so your body may clear lurasidone faster than usual.

That could mean lower lurasidone levels and less benefit, so symptoms might return or feel harder to control. The effect gets stronger at higher mitapivat doses. Please keep taking both exactly as prescribed. Let your pharmacist or doctor know you take both. They can watch how you are doing and may adjust your lurasidone dose to keep it working well.

Mechanism: Mitapivat is a . Lurasidone is a sensitive , so is expected to lower its exposure (PK interaction, reduced and ). Lurasidone is not a .

  • Magnitude: Not studied with lurasidone. With midazolam, AUC fell 21% (5 mg BID), 43% (20 mg BID), 57% (50 mg BID) and 65% (100 mg BID), a dose-dependent effect.
  • Onset: Unspecified. Evidence: Probable.
  • Risk: Loss of or antidepressant , with possible relapse.
  • Management: Labeling advises avoiding sensitive CYP3A substrates with a . If is required, monitor for loss of therapeutic effect. Lurasidone dose may need individualized adjustment based on clinical response.

See the 3 references behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Mitapivat and Lurasidone Interact

The likely mechanism

of -mediated by mitapivat

How Drug Interactions Work Six short figures, about a minute: how one drug can raise or lower another’s level, or add to or cancel its effect. See how it works 

How to Manage the Mitapivat and Lurasidone Interaction

Your care team can manage this by tailoring your treatment and following you more closely.

  • Keep taking both medicines as prescribed. Do not stop or change either one on your own.
  • If both are needed, your team will typically monitor for loss of lurasidone effect, and your lurasidone dose may need to be adjusted and individualized.
  • Tell your pharmacist or prescriber if mood, thinking, sleep, or other symptoms start to return or worsen.
  • Mention any change in your mitapivat dose, since the effect grows with higher doses.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Mitapivat or Lurasidone need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there another option that avoids this interaction?

Literature Reports

1 report from the published literature. Each one is headed by the title of the published study it comes from.

What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.

  1. Report 1 · Study title

    Prescribing information: PYRUKYND oral tablets, mitapivat oral tablets

    In drug interaction studies, giving mitapivat together with midazolam (a sensitive ) lowered midazolam (inf) and by 21% and 19% with mitapivat 5 mg twice daily, by 43% and 39% with mitapivat 20 mg twice daily, and by 57% and 52% with mitapivat 50 mg twice daily, respectively.3 In a similar finding, midazolam AUC (inf) and Cmax were reduced by 65% and 59%, respectively, with mitapivat 100 mg twice daily.1

Mitapivat and Lurasidone: Common Questions

How serious is the Mitapivat and Lurasidone interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How is the Mitapivat and Lurasidone interaction managed?

Your care team can manage this by tailoring your treatment and following you more closely. Keep taking both medicines as prescribed. Do not stop or change either one on your own. If both are needed, your team will typically monitor for loss of lurasidone effect, and your lurasidone dose may need to be adjusted and individualized. Tell your pharmacist or prescriber if mood, thinking, sleep, or othe… Management is individual — always follow your own care team's guidance.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "probable". Good supporting evidence, though not definitively proven.

Ask About the Mitapivat and Lurasidone Interaction

Ask in your own words about taking Mitapivat and Lurasidone together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (3)

  1. Product Information: AQVESME™ oral tablets, mitapivat oral tablets. Agios Pharmaceuticals Inc (per FDA), Cambridge, MA, 2025. DailyMed
  2. Product Information: PYRUKYND(R) oral tablets, mitapivat oral tablets. Agios Pharmaceuticals Inc (per FDA), Cambridge, MA, 2022. DailyMed
  3. Product Information: PYRUKYND(R) oral tablets, mitapivat oral tablets. Agios Pharmaceuticals Inc (per FDA), Cambridge, MA, 2025. DailyMed
Was this write-up helpful?

Other Serious Interactions of Mitapivat and Lurasidone

Also serious with Lurasidone

Also serious with Mitapivat

These Medications Also Interact With Supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

With Lurasidone

With Mitapivat

Check everything you take with our drug–supplement interaction checker.

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, as soon as they can.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together.
  • Major Potentially serious — often needs a change or close monitoring. This interaction.
  • Moderate Can be significant — usually manageable with monitoring.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data.
  • ProbableGood supporting evidence, though not definitively proven. This interaction.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks.
  • UnspecifiedThe timing of this interaction is not well characterized. This interaction.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.